Promising malaria vaccine enters key trial in africa
NCT ID NCT07385287
First seen Feb 04, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests a new malaria vaccine (PfSPZ-LARC2) in 180 healthy adults aged 18-50 in Burkina Faso. The vaccine uses weakened malaria parasites that grow in the liver but stop there, training the immune system without causing blood-stage infection. Participants receive one or two doses of the vaccine or a placebo, and researchers will monitor for malaria infections over 24 weeks to see if the vaccine provides protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.